Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX 110, for the treatment of various human respiratory diseases or conditions; PRX 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX 119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Company Details
- Employees
- 192
- Founded
- -
- Address
- 2 Snunit St., Science Park, Pob 455,israel
- Phone
- 972-4-902-8100
- bd****@****lix.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- protalix.com
- Keywords
- Manager jobs.
- HQ
- Carmiel
Protalix Biotherapeutics Questions
Protalix Biotherapeutics's helpline number is 972-4-902-8100
Protalix Biotherapeutics's website is protalix.com
Protalix Biotherapeutics's LinkedIn profile is https://il.linkedin.com/company/protalix-biotherapiutics
Protalix Biotherapeutics has
192 employees.
View email and phone details for 192
employees at Protalix Biotherapeutics.
Protalix Biotherapeutics's industry is
Biotechnology Research
Protalix Biotherapeutics's top competitors are
Anima Biotech,
Evogene,
Cytoreason,
Bonus Biogroup,
Pluri,
Memed,
Biolinerx,
Biomx (Nyse: Phge),
Novocure,
Dexcel Pharma.
Protalix Biotherapeutics's support email address is bd@protalix.com
Protalix Biotherapeutics's categories are Biotechnology Research
Protalix Biotherapeutics's founding year is 1994
